The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Origin and evolution of the 1918 “Spanish” influenza virus hemagglutinin gene
Reid, A. H., Fanning, T. G., Hultin, J. V., & Taubenberger, J. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1651 · Cited by 607
Clinical effectiveness of influenza vaccination in Manitoba.
Fedson, D. S. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510160074032 · Cited by 278
Research works printed but not linked: 32
- Davies, 1964, Antiviral activity of 1-ada mantanamine (amantadine), Science, 144, 826, 10.1126/science.144.3620.862 · DOI · Paper page
- Hay, 1985, The molecular basis of the specific anti-influenza action of amantadine, EMBO J, 4, 3021, 10.1002/j.1460-2075.1985.tb04038.x · DOI · Paper page
- Aoki, 1988, Clinical pharmacokinetics of amantadine hydrochloride, Clin Pharmacokinet, 14, 35, 10.2165/00003088-198814010-00003 · DOI · Paper page
- Oxford, 1984, Anti influenza virus activity of amantadine, Viral Chemother, 1, 169
- Welliver, 2001, Effectiveness of oseltamivir in preventing influenza in household contacts, JAMA, 285, 748, 10.1001/jama.285.6.748 · DOI · Paper page
- Hayden, 2000, Inhaled zanamivir for the prevention of influenza in families, N Engl J Med, 343, 778, 10.1056/NEJM200011023431801 · DOI · Paper page
- Reuman, 1989, Efficacy and safety of low dose amantadine hydrochloride as prophylaxis for influenza A, Antiviral Res, 11, 27, 10.1016/0166-3542(89)90018-1 · DOI
- Oxford, 1970, In vivo selection of an influenza A2 strain resistant to amantadine, Nature Lond, 226, 82, 10.1038/226082a0 · DOI
- Smorodintsev, 1970, Evaluation of amantadine in artificially induced A2 and B influenza, JAMA, 213, 1448, 10.1001/jama.1970.03170350016003 · DOI
- Younkin, 1983, Reduction in fever in young adults with influenza A/Brazil 78, H1, N1 infection after treatment with aspirin or amantadine, Antimicrob Agents Chemother, 23, 577, 10.1128/AAC.23.4.577 · doi:10.1128/aac.23.4.577
- Sears, 1987, Protective efficacy of low dose amantadine in adults challenged with wild-type influenza A virus, Antimicrob Agents Chemother, 31, 1470, 10.1128/AAC.31.10.1470 · DOI
- Laver, 1964, Structural studies on the protein subunits from three strains of influenza virus, J Mol Biol, 9, 109, 10.1016/S0022-2836(64)80094-2 · DOI · Paper page
- Colman, 1983, Structure of the catalytic and antigenic sites in influenza virus neuraminidase, Nature, 303, 41, 10.1038/303041a0 · DOI · Paper page
- Meindl, 1969, Hoppe Seyler's Z Physiol Chem, 350, 1088, 10.1515/bchm2.1969.350.2.1088 · DOI
- Laver, 1999, Disarming flu viruses, Scientific Am, 280, 78, 10.1038/scientificamerican0199-78 · doi:10.1038/scientificamerican0199-78
- Ives, 2002, The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo, Antiviral Res, 55, 307, 10.1016/S0166-3542(02)00053-0 · DOI · Paper page
- Gubareva, 2000, Influenza virus neuraminidase inhibitors, Lancet, 355, 827, 10.1016/S0140-6736(99)11433-8 · DOI · Paper page
- Mendel, 1997, GS 4071 is a potent and selective inhibitor of the growth and neuraminidase activity of influenza A and B virus in vitro, Antiviral Res, 34, A73, 10.1016/S0166-3542(97)83251-2 · doi:10.1016/s0166-3542(97)83251-2
- Brouillette, 1999, Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping, Bioorganic Med Cem Lett, 9, 1901, 10.1016/S0960-894X(99)00318-2 · DOI
- Luo, 1997, Design of aromatic inhibitors of influenza virus neuraminidase, J Infect Dis, 176, S62, 10.1086/514178 · DOI
- Kim, 1998, Structure–activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors, J Med Chem, 41, 2451, 10.1021/jm980162u · DOI · Paper page
- Hayden, 1996, Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza, JAMA, 275, 24, 10.1001/jama.1996.03530280047035 · DOI · Paper page
- Makela, 2000, Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomised, double-blind, placebo-controlled European study, J Infect, 40, 42, 10.1053/jinf.1999.0602 · DOI · Paper page
- Monto, 1999, Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections, J Infect Dis, 180, 254, 10.1086/314904 · DOI · Paper page
- Oxford, 1998, Targeting influenza virus neuraminidase—a new strategy for antiviral therapy, Drug Discovery Today, 3, 448, 10.1016/S1359-6446(98)01241-0 · DOI
- Nicholson, 2000, Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial, Lancet, 355, 1845, 10.1016/S0140-6736(00)02288-1 · DOI · Paper page
- Treanor, 2000, Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza, JAMA, 283, 1016, 10.1001/jama.283.8.1016 · DOI · Paper page
- Oxford, 2001
- Public Health Laboratory Service, 1993, Response to a pandemic of influenza: an action plan, PHLS Digest, 10, 147
- Oxford, 2000, InfluenzaApandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology, Rev Med Virol, 10, 119, 10.1002/(SICI)1099-1654(200003/04)10:2<119::AID-RMV272>3.0.CO;2-O · DOI
- Meltzer, 1999, The economic impact of pandemic influenza in the United States: priorities for intervention, Emerg Infect Dis, 5, 659, 10.3201/eid0505.990507 · DOI · Paper page
- Davis, 2000, Ground penetrating radar survey to locate 1918 Spanish flu victims in permafrost, J Forensic Sci, 20, 68, 10.1520/JFS14642J · DOI
Cited by
Anti-infective potential of natural products: How to develop a stronger in vitro ‘proof-of-concept’
Cos, P., Vlietinck, A. J., Berghe, D. V., & Maes, L. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.04.003 · Cited by 1,603
Setting and Revising Antibacterial Susceptibility Breakpoints
Turnidge, J., & Paterson, D. L. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-06 · Cited by 578
Almirante, B., Rodríguez, D., Park, B. J., Cuenca-Estrella, M., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J., Gimenez, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1829-1835.2005 · Cited by 566
Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease
Munoz, P., Bouza, E., Cuenca-Estrella, M., Eiros, J. M., Perez, M. J., Sanchez-Somolinos, M., Rincon, C., Hortal, J., & Pelaez, T. (2005) · Clinical Infectious Diseases · doi:10.1086/429916 · Cited by 462
Drug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H., Haw, T. Y., Nutsford, A., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 439
Metadata
- Authors
- Oxford, J. S., Bossuyt, S., Balasingam, S., Mann, A., Novelli, P., & Lambkin, R.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 9
- Issue
- 1
- Pages
- 1-14
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W1757353225
- Cited by
- 233
- References
- 4
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4352 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. https://app.cochat.ai/papers/10.1046/j.1469-0691.2003.00564.x
- The paper
- Oxford, J. S., Bossuyt, S., Balasingam, S., Mann, A., Novelli, P., & Lambkin, R. (2003). Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clinical Microbiology and Infection. https://doi.org/10.1046/j.1469-0691.2003.00564.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.